Korea Investment CORP trimmed its holdings in Bausch Health Companies Inc (NYSE:BHC) by 45.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,092 shares of the company’s stock after selling 18,344 shares during the period. Korea Investment CORP’s holdings in Bausch Health Companies were worth $408,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. ValueAct Holdings L.P. purchased a new position in Bausch Health Companies during the 3rd quarter worth $462,911,000. Vanguard Group Inc. purchased a new position in Bausch Health Companies during the 3rd quarter worth $223,173,000. Vanguard Group Inc purchased a new position in Bausch Health Companies during the 3rd quarter worth $223,173,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Bausch Health Companies by 0.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock worth $156,267,000 after purchasing an additional 75,175 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in Bausch Health Companies during the 3rd quarter worth $135,538,000. Hedge funds and other institutional investors own 53.02% of the company’s stock.

Shares of NYSE:BHC opened at $23.98 on Friday. Bausch Health Companies Inc has a 12-month low of $14.95 and a 12-month high of $28.45. The firm has a market capitalization of $8.39 billion, a PE ratio of 5.97, a P/E/G ratio of 0.30 and a beta of 0.58. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 8.55.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, February 20th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.84 by $0.21. Bausch Health Companies had a positive return on equity of 39.91% and a negative net margin of 50.83%. The business had revenue of $2.12 billion for the quarter, compared to the consensus estimate of $2.08 billion. During the same period last year, the business posted $0.98 EPS. The business’s revenue was down 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Bausch Health Companies Inc will post 3.98 EPS for the current year.

BHC has been the topic of several research reports. Morgan Stanley set a $32.00 price objective on Bausch Health Companies and gave the stock a “buy” rating in a report on Monday, December 17th. HC Wainwright upgraded Bausch Health Companies from an “average” rating to a “buy” rating in a report on Friday, December 14th. UBS Group upgraded Bausch Health Companies to a “buy” rating in a report on Wednesday, January 2nd. Mizuho restated a “buy” rating and set a $39.00 price objective on shares of Bausch Health Companies in a report on Sunday, January 6th. Finally, Zacks Investment Research upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a report on Tuesday, January 29th. Three analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $27.61.

In other Bausch Health Companies news, CEO Joseph C. Papa acquired 30,000 shares of the stock in a transaction dated Thursday, February 28th. The stock was purchased at an average price of $23.67 per share, with a total value of $710,100.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 11.54% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Bausch Health Companies Inc (BHC) Stake Decreased by Korea Investment CORP” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/bausch-health-companies-inc-bhc-stake-decreased-by-korea-investment-corp/2897608.html.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Featured Story: Bid-Ask Spread

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.